Needham & Company LLC Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) Stock

Liquidia (NASDAQ:LQDA) had its target price raised by analysts at Needham & Company LLC from $52.00 to $54.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 49.88% from the company’s previous close.

Other equities analysts have also issued reports about the stock. Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research note on Thursday. Jefferies Financial Group upped their target price on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, January 13th. Finally, Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Liquidia Stock Performance

LQDA stock opened at $36.03 on Thursday. Liquidia has a one year low of $11.26 and a one year high of $46.67. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of -43.41, a PEG ratio of 0.60 and a beta of 0.52. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The firm has a 50-day simple moving average of $37.10 and a two-hundred day simple moving average of $30.89.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The firm had revenue of $92.02 million during the quarter. Liquidia had a negative return on equity of 237.79% and a negative net margin of 43.53%.The company’s quarterly revenue was up 3072.4% on a year-over-year basis. On average, equities analysts forecast that Liquidia will post -1.51 EPS for the current fiscal year.

Insider Transactions at Liquidia

In related news, insider Scott Moomaw sold 20,533 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $768,550.19. Following the transaction, the insider owned 154,514 shares in the company, valued at approximately $5,783,459.02. This represents a 11.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Roger Jeffs sold 66,610 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $2,493,212.30. Following the transaction, the chief executive officer directly owned 1,037,528 shares of the company’s stock, valued at $38,834,673.04. This represents a 6.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 212,534 shares of company stock valued at $7,964,719. 26.50% of the stock is owned by company insiders.

Institutional Trading of Liquidia

Several large investors have recently made changes to their positions in LQDA. Farallon Capital Management LLC increased its stake in shares of Liquidia by 1.1% in the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after acquiring an additional 90,400 shares during the period. Vanguard Group Inc. lifted its position in Liquidia by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock valued at $138,439,000 after purchasing an additional 52,671 shares during the period. Opaleye Management Inc. lifted its position in Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after purchasing an additional 215,000 shares during the period. Caprock Group LLC boosted its holdings in Liquidia by 9.3% in the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock valued at $61,527,000 after purchasing an additional 151,832 shares during the last quarter. Finally, TCG Crossover Management LLC acquired a new stake in Liquidia during the 3rd quarter worth about $38,887,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).